An integrated view of cisplatin-induced nephrotoxicity and ototoxicity

Toxicology Letters

Volumn 237, Issue 3, 2015, Pages 219-227

  Karasawa, Takatoshi ^a   Steyger, Peter S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cisplatin; Intracellular mechanisms; Nephrotoxicity; Ototoxicity

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; ANTIOXIDANT; BINDING PROTEIN; CISPLATIN; CYTOPLASM PROTEIN; HEAT SHOCK PROTEIN 90; ORGANIC CATION TRANSPORTER 2; PLATINUM DERIVATIVE; PROCAINAMIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL DEATH; COCHLEA; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; HAIR CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEPHROTOXICITY; NERVE CELL; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPIRAL GANGLIA; SPIRAL GANGLION; STRIA VASCULARIS; CHEMICALLY INDUCED; KIDNEY DISEASE; METABOLISM; PATHOLOGY; VESTIBULAR DISORDER;

ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; KIDNEY DISEASES; REACTIVE OXYGEN SPECIES; VESTIBULAR DISEASES;

EID: 84934764055     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2015.06.012     Document Type: Review

References (138)

1. Aabo K., Adams M., Adnitt P., Alberts D.S., Athanazziou A., Barley V., Bell D.R., Bianchi U., Bolis G., Brady M.F., Brodovsky H.S., Bruckner H., Buyse M., Canetta R., Chylak V., Cohen C.J., Colombo N., Conte P.F., Crowther D., Edmonson J.H., Gennatas C., Gilbey E., Gore M., Guthrie D., Yeap B.Y., et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br. J. Cancer 1998, 78:1479-1487.
2. Akcay A., Turkmen K., Lee D., Edelstein C.L. Update on the diagnosis and management of acute kidney injury. Int. J. Nephrol. Renovasc. Dis. 2010, 3:129-140.
3. Alharazneh A., Luk L., Huth M., Monfared A., Steyger P.S., Cheng A.G., Ricci A.J. Functional hair cell mechanotransducer channels are required for aminoglycoside ototoxicity. PLoS One 2011, 6:e22347.
4. Arany I., Megyesi J.K., Kaneto H., Price P.M., Safirstein R.L. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am. J. Physiol. Renal Physiol. 2004, 287:F543-F549.
5. Assad J.A., Shepherd G.M., Corey D.P. Tip-link integrity and mechanical transduction in vertebrate hair cells. Neuron 1991, 7:985-994.
6. Banfi B., Malgrange B., Knisz J., Steger K., Dubois-Dauphin M., Krause K.H. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J. Biol. Chem. 2004, 279:46065-46072.
7. Berger K., Moeller M.J. Mechanisms of epithelial repair and regeneration after acute kidney injury. Semin. Nephrol. 2014, 34:394-403.
8. Bess F.H., Dodd-Murphy J., Parker R.A. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 1998, 19:339-354.
9. Boersma A.W., Nooter K., Burger H., Kortland C.J., Stoter G. Bax upregulation is an early event in cisplatin-induced apoptosis in human testicular germ-cell tumor cell line NT2, as quantitated by flow cytometry. Cytometry 1997, 27:275-282.
10. Bokemeyer C., Berger C.C., Hartmann J.T., Kollmannsberger C., Schmoll H.J., Kuczyk M.A., Kanz L. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Cancer 1998, 77:1355-1362.
11. Boven E., Verschraagen M., Hulscher T.M., Erkelens C.A., Hausheer F.H., Pinedo H.M., van der Vijgh W.J. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur. J. Cancer 2002, 38:1148-1156.
12. Brock P.R., Knight K.R., Freyer D.R., Campbell K.C., Steyger P.S., Blakley B.W., Rassekh S.R., Chang K.W., Fligor B.J., Rajput K., Sullivan M., Neuwelt E.A. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J. Clin. Oncol. 2012, 30:2408-2417.
13. Campbell K.C., Rybak L.P., Meech R.P., Hughes L. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996, 102:90-98.
14. Cardinaal R.M., de Groot J.C., Huizing E.H., Veldman J.E., Smoorenburg G.F. Histological effects of co-administration of an ACTH((4-9)) analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig. Hear Res. 2000, 144:157-167.
15. Carleton B., Poole R., Smith M., Leeder J., Ghannadan R., Ross C., Phillips M., Hayden M. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiol. Drug Saf. 2009, 18:713-721.
16. Caronia D., Patino-Garcia A., Milne R.L., Zalacain-Diez M., Pita G., Alonso M.R., Moreno L.T., Sierrasesumaga-Ariznabarreta L., Benitez J., Gonzalez-Neira A. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 2009, 9:347-353.
17. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
18. Chakraborty A., Koldobskiy M.A., Sixt K.M., Juluri K.R., Mustafa A.K., Snowman A.M., van Rossum D.B., Patterson R.L., Snyder S.H. HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc. Natl. Acad. Sci. U.S.A 2008, 105:1134-1139.
19. Ciarimboli G., Deuster D., Knief A., Sperling M., Holtkamp M., Edemir B., Pavenstadt H., Lanvers-Kaminsky C., am Zehnhoff-Dinnesen A., Schinkel A.H., Koepsell H., Jurgens H., Schlatter E. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 2010, 176:1169-1180.
20. Clerici W.J., DiMartino D.L., Prasad M.R. Direct effects of reactive oxygen species on cochlear outer hair cell shape in vitro. Hear Res. 1995, 84:30-40.
21. Cooper L.B., Chan D.K., Roediger F.C., Shaffer B.R., Fraser J.F., Musatov S., Selesnick S.H., Kaplitt M.G. AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity. Otol. Neurotol. 2006, 27:484-490.
22. Cornelison T.L., Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol. Oncol. 1993, 50:147-158.
23. Cummings B.S., Schnellmann R.G. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 2002, 302:8-17.
24. Cummings B.S., McHowat J., Schnellmann R.G. Role of an endoplasmic reticulum Ca2+-independent phospholipase A2 in cisplatin-induced renal cell apoptosis. J. Pharmacol. Exp. Ther. 2004, 308:921-928.
25. Deng J., Kohda Y., Chiao H., Wang Y., Hu X., Hewitt S.M., Miyaji T., McLeroy P., Nibhanupudy B., Li S., Star R.A. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001, 60:2118-2128.
26. Devarajan P., Savoca M., Castaneda M.P., Park M.S., Esteban-Cruciani N., Kalinec G., Kalinec F. Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res. 2002, 174:45-54.
27. Dickey D.T., Wu Y.J., Muldoon L.L., Neuwelt E.A. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J. Pharmacol. Exp. Ther. 2005, 314:1052-1058.
28. Einhorn L.H. Curing metastatic testicular cancer. Proc. Natl. Acad. Sci. U.S.A 2002, 99:4592-4595.
29. Faivre S., Kalla S., Cvitkovic E., Bourdon O., Hauteville D., Dourte L.M., Bensmaine M.A., Itzhaki M., Marty M., Extra J.M. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann. Oncol. 1999, 10:1125-1128.
30. Farris H.E., LeBlanc C.L., Goswami J., Ricci A.J. Probing the pore of the auditory hair cell mechanotransducer channel in turtle. J. Physiol. 2004, 558:769-792.
31. Faubel S., Ljubanovic D., Reznikov L., Somerset H., Dinarello C.A., Edelstein C.L. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int. 2004, 66:2202-2213.
32. Faubel S., Lewis E.C., Reznikov L., Ljubanovic D., Hoke T.S., Somerset H., Oh D.J., Lu L., Klein C.L., Dinarello C.A., Edelstein C.L. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J. Pharmacol. Exp. Ther. 2007, 322:8-15.
33. Filipski K.K., Mathijssen R.H., Mikkelsen T.S., Schinkel A.H., Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 2009, 86:396-402.
34. Francescato H.D., Costa R.S., Junior F.B., Coimbra T.M. Effect of JNK inhibition on cisplatin-induced renal damage. Nephrol. Dial. Transplant. 2007, 22:2138-2148.
35. Fuertes M.A., Alonso C., Perez J.M. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 2003, 103:645-662.
36. Guthrie O.W., Li-Korotky H.S., Durrant J.D., Balaban C. Cisplatin induces cytoplasmic to nuclear translocation of nucleotide excision repair factors among spiral ganglion neurons. Hear Res. 2008, 239:79-91.
37. Hannemann J., Baumann K. Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study. Arch. Toxicol. 1990, 64:393-400.
38. Hannemann J., Duwe J., Baumann K. Iron- and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds. Cancer Chemother. Pharmacol. 1991, 28:427-433.
39. Harned T.M., Kalous O., Neuwelt A., Loera J., Ji L., Iovine P., Sposto R., Neuwelt E.A., Reynolds C.P. Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin. Cancer Res. 2008, 14:533-540.
40. Harrap K.R. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 1985, 12(Suppl A):21-33.
41. Hellberg V., Gahm C., Liu W., Ehrsson H., Rask-Andersen H., Laurell G. Immunohistochemical localization of OCT2 in the cochlea of various species. Laryngoscope 2015, 10.1002/lary.25304.
42. Hensley M.L., Hagerty K.L., Kewalramani T., Green D.M., Meropol N.J., Wasserman T.H., Cohen G.I., Emami B., Gradishar W.J., Mitchell R.B., Thigpen J.T., Trotti A., von Hoff D., Schuchter L.M. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 2009, 27:127-145.
43. Henson E.S., Gibson S.B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell. Signal. 2006, 18:2089-2097.
44. Hilder T.A., Hill J.M. Modelling the encapsulation of the anticancer drug cisplatin into carbon nanotubes. Nanotechnology 2007, 18:275704.
45. Hudspeth A.J., Corey D.P. Sensitivity, polarity, and conductance change in the response of vertebrate hair cells to controlled mechanical stimuli. Proc. Natl. Acad. Sci. U.S.A 1977, 74:2407-2411.
46. Hudspeth A.J. The ionic channels of a vertebrate hair cell. Hear Res. 1986, 22:21-27.
47. Ikeda K., Sunose H., Takasaka T. Effects of free radicals on the intracellular calcium concentration in the isolated outer hair cell of the guinea pig cochlea. Acta Otolaryngol. 1993, 113:137-141.
48. Jacobs S.S., Fox E., Dennie C., Morgan L.B., McCully C.L., Balis F.M. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin. Cancer Res. 2005, 11:1669-1674.
49. Jakob S.M., Arnold W., Marti H.P. Progressive renal failure after cisplatin therapy. Nephrol. Dial. Transplant. 1996, 11:370-373.
50. Jamesdaniel S., Coling D., Hinduja S., Ding D., Li J., Cassidy L., Seigel G.M., Qu J., Salvi R. Cisplatin-induced ototoxicity is mediated by nitroxidative modification of cochlear proteins characterized by nitration of Lmo4. J. Biol. Chem. 2012, 287:18674-18686.
51. Jamieson E.R., Lippard S.J. Structure, Recognition, and Processing of Cisplatin DNA Adducts. Chem. Rev. 1999, 99:2467-2498.
52. Jekunen A.P., Hom D.K., Alcaraz J.E., Eastman A., Howell S.B. Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells. Cancer Res. 1994, 54:2680-2687.
53. Jiang M., Yi X., Hsu S., Wang C.Y., Dong Z. Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am. J. Physiol. 2004, 287:F1140-F1147.
54. Jiang M., Wei Q., Wang J., Du Q., Yu J., Zhang L., Dong Z. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 2006, 25:4056-4066.
55. Juo P., Kuo C.J., Yuan J., Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr. Biol. 1998, 8:1001-1008.
56. Karasawa T., Sibrian-Vazquez M., Strongin R.M., Steyger P.S. Identification of cisplatin-binding proteins using agarose conjugates of platinum compounds. PLoS One 2013, 8:e66220.
57. Kaur T., Mukherjea D., Sheehan K., Jajoo S., Rybak L.P., Ramkumar V. Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation. Cell Death Dis. 2011, 2:e180.
58. Khynriam D., Prasad S.B. Changes in glutathione-related enzymes in tumor-bearing mice after cisplatin treatment. Cell Biol. Toxicol. 2002, 18:349-358.
59. Kidera Y., Kawakami H., Sakiyama T., Okamoto K., Tanaka K., Takeda M., Kaneda H., Nishina S., Tsurutani J., Fujiwara K., Nomura M., Yamazoe Y., Chiba Y., Nishida S., Tamura T., Nakagawa K. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One 2014, 9:e101902.
60. Kim H.J., Lee J.H., Kim S.J., Oh G.S., Moon H.D., Kwon K.B., Park C., Park B.H., Lee H.K., Chung S.Y., Park R., So H.S. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J. Neurosci. 2010, 30:3933-3946.
61. Knight K.R., Kraemer D.F., Neuwelt E.A. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J. Clin. Oncol. 2005, 23:8588-8596.
62. Knight K.R., Kraemer D.F., Winter C., Neuwelt E.A. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J. Clin. Oncol. 2007, 25:1190-1195.
63. Knox R.J., Friedlos F., Lydall D.A., Roberts J.J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986, 46:1972-1979.
64. Koo J.W., Quintanilla-Dieck L., Jiang M., Liu J., Urdang Z.D., Allensworth J.J., Cross C.P., Li H., Steyger P.S. Endotoxemia-mediated inflammation potentiates aminoglycoside-induced ototoxicity. Sci. Transl. Med. 2015, (in press).
65. Kruidering M., Van de Water B., de Heer E., Mulder G.J., Nagelkerke J.F. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J. Pharmacol. Exp. Ther. 1997, 280:638-649.
66. Lanvers-Kaminsky C., Sprowl J.A., Malath I., Deuster D., Eveslage M., Schlatter E., Mathijssen R.H., Boos J., Jurgens H., Am Zehnhoff-Dinnesen A.G., Sparreboom A., Ciarimboli G. Human OCT2 variant c.808G
67. Laurell G., Engstrom B. The combined effect of cisplatin and furosemide on hearing function in guinea pigs. Hear Res. 1989, 38:19-26.
68. Laurell G., Viberg A., Teixeira M., Sterkers O., Ferrary E. Blood-perilymph barrier and ototoxicity: an in vivo study in the rat. Acta Otolaryngol. 2000, 120:796-803.
69. Laurell G., Ekborn A., Viberg A., Canlon B. Effects of a single high dose of cisplatin on the melanocytes of the stria vascularis in the guinea pig. Audiol. Neurootol. 2007, 12:170-178.
70. Lee R.H., Song J.M., Park M.Y., Kang S.K., Kim Y.K., Jung J.S. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem. Pharmacol. 2001, 62:1013-1023.
71. Li H., Steyger P.S. Systemic aminoglycosides are trafficked via endolymph into cochlear hair cells. Sci. Rep. 2011, 1:159.
72. Li G., Frenz D.A., Brahmblatt S., Feghali J.G., Ruben R.J., Berggren D., Arezzo J., Van De Water T.R. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology 2001, 22:163-176.
73. Li G., Liu W., Frenz D. Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS. Neurotoxicology 2006, 27:22-30.
74. Liu H., Baliga R. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003, 63:1687-1696.
75. Liu H., Baliga R. Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J. Am. Soc. Nephrol. 2005, 16:1985-1992.
76. Lu L.H., Oh D.J., Dursun B., He Z., Hoke T.S., Faubel S., Edelstein C.L. Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice. J. Pharmacol. Exp. Ther. 2008, 324:111-117.
77. Lu X., Wang L., Ruden D.M. Hsp90 inhibitors and the reduction of anti-cancer drug resistance by non-genetic and genetic mechanisms. Pharmaceuticals 2012, 5:890-898.
78. Marcotti W., van Netten S.M., Kros C.J. The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-electrical transducer channels. J. Physiol. 2005, 567:505-521.
79. Marullo R., Werner E., Degtyareva N., Moore B., Altavilla G., Ramalingam S.S., Doetsch P.W. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One 2013, 8:e81162.
80. McWhinney S.R., Goldberg R.M., McLeod H.L. Platinum neurotoxicity pharmacogenetics. Mol. Cancer Ther. 2009, 8:10-16.
81. Mishima K., Baba A., Matsuo M., Itoh Y., Oishi R. Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic. Biol. Med. 2006, 40:1564-1577.
82. Mohr P.E., Feldman J.J., Dunbar J.L., McConkey-Robbins A., Niparko J.K., Rittenhouse R.K., Skinner M.W. The societal costs of severe to profound hearing loss in the United States. Int. J. Technol. Assess. Health Care 2000, 16:1120-1135.
83. Molitoris B.A., Dagher P.C., Sandoval R.M., Campos S.B., Ashush H., Fridman E., Brafman A., Faerman A., Atkinson S.J., Thompson J.D., Kalinski H., Skaliter R., Erlich S., Feinstein E. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J. Am. Soc. Nephrol. 2009, 20:1754-1764.
84. More S.S., Akil O., Ianculescu A.G., Geier E.G., Lustig L.R., Giacomini K.M. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J. Neurosci. 2010, 30:9500-9509.
85. Mukherjea D., Whitworth C.A., Nandish S., Dunaway G.A., Rybak L.P., Ramkumar V. Expression of the kidney injury molecule 1 in the rat cochlea and induction by cisplatin. Neuroscience 2006, 139:733-740.
86. Mukherjea D., Jajoo S., Whitworth C., Bunch J.R., Turner J.G., Rybak L.P., Ramkumar V. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. J. Neurosci. 2008, 28:13056-13065.
87. Mukherjea D., Jajoo S., Kaur T., Sheehan K.E., Ramkumar V., Rybak L.P. Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat. Antioxid. Redox Signal. 2010, 13:589-598.
88. Mukherjea D., Jajoo S., Sheehan K., Kaur T., Sheth S., Bunch J., Perro C., Rybak L.P., Ramkumar V. NOX3 NADPH oxidase couples transient receptor potential vanilloid 1 to signal transducer and activator of transcription 1-mediated inflammation and hearing loss. Antioxid. Redox Signal. 2011, 14:999-1010.
89. Mukherjea D., Rybak L.P., Sheehan K.E., Kaur T., Ramkumar V., Jajoo S., Sheth S. The design and screening of drugs to prevent acquired sensorineural hearing loss. Expert Opin. Drug Deliv. 2011, 6:491-505.
90. Mukhopadhyay P., Rajesh M., Pan H., Patel V., Mukhopadhyay B., Batkai S., Gao B., Hasko G., Pacher P. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic. Biol. Med. 2010, 48:457-467.
91. Oh G.S., Kim H.J., Choi J.H., Shen A., Kim C.H., Kim S.J., Shin S.R., Hong S.H., Kim Y., Park C., Lee S.J., Akira S., Park R., So H.S. Activation of lipopolysaccharide-TLR4 signaling accelerates the ototoxic potential of cisplatin in mice. J. Immunol. 2011, 186:1140-1150.
92. Pabla N., Murphy R.F., Liu K., Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Renal Physiol. 2009, 296:F505-F511.
93. Park M.S., De Leon M., Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J. Am. Soc. Nephrol. 2002, 13:858-865.
94. Pickles J.O., Comis S.D., Osborne M.P. Cross-links between stereocilia in the guinea pig organ of Corti, and their possible relation to sensory transduction. Hear Res. 1984, 15:103-112.
95. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., Oshima M., Fujii C., Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 2008, 118:560-570.
96. Price P.M., Safirstein R.L., Megyesi J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am. J. Physiol. Renal Physiol. 2004, 286:378F-3384. F378.
97. Ramesh G., Reeves W.B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 2002, 110:835-842.
98. Ramesh G., Reeves W.B. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am. J. Physiol. Renal Physiol. 2005, 289:F166-174.
99. Rosell R., Taron M., Barnadas A., Scagliotti G., Sarries C., Roig B. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003, 10:297-305.
100. Rosenberg B., Vancamp L., Krigas T. Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a PlatinumElectrode. Nature 1965, 205:698-699.
101. Rosenberg B., VanCamp L., Trosko J.E., Mansour V.H. Platinum compounds: a new class of potent antitumour agents. Nature 1969, 222:385-386.
102. Ross C.J., Katzov-Eckert H., Dube M.P., Brooks B., Rassekh S.R., Barhdadi A., Feroz-Zada Y., Visscher H., Brown A.M., Rieder M.J., Rogers P.C., Phillips M.S., Carleton B.C., Hayden M.R. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 2009, 41:1345-1349.
103. Roy S., Ryals M.M., Van den Bruele A.B., Fitzgerald T.S., Cunningham L.L. Sound preconditioning therapy inhibits ototoxic hearing loss in mice. J. Clin. Invest. 2013, 123:4945-4949.
104. Rybak L.P., Ramkumar V. Ototoxicity. Kidney Int. 2007, 72:931-935.
105. Rybak L.P., Whitworth C.A., Mukherjea D., Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 2007, 226:157-167.
106. Rybak L.P., Mukherjea D., Jajoo S., Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J. Exp. Med. 2009, 219:177-186.
107. Sadzuka Y., Shoji T., Takino Y. Mechanism of the increase in lipid peroxide induced by cisplatin in the kidneys of rats. Toxicol. Lett. 1992, 62:293-300.
108. Schilsky R.L., Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann. Intern. Med. 1979, 90:929-931.
109. Schmitt N.C., Rubel E.W., Nathanson N.M. Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. J. Neurosci. 2009, 29:3843-3851.
110. Seth R., Yang C., Kaushal V., Shah S.V., Kaushal G.P. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J. Biol. Chem. 2005, 280:31230-31239.
111. Shen D.W., Pouliot L.M., Hall M.D., Gottesman M.M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 2012, 64:706-721.
112. Skinner R., Pearson A.D., English M.W., Price L., Wyllie R.A., Coulthard M.G., Craft A.W. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br. J. Cancer 1998, 77:1677-1682.
113. Slattery E.L., Warchol M.E. Cisplatin ototoxicity blocks sensory regeneration in the avian inner ear. J. Neurosci. 2010, 30:3473-3481.
114. Slattery E.L., Oshima K., Heller S., Warchol M.E. Cisplatin exposure damages resident stem cells of the mammalian inner ear. Dev. Dyn. 2014, 243:1328-1337.
115. So H., Kim H., Lee J.H., Park C., Kim Y., Kim E., Kim J.K., Yun K.J., Lee K.M., Lee H.Y., Moon S.K., Lim D.J., Park R. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J. Assoc. Res. Otolaryngol. 2007, 8:338-355.
116. Sprowl J.A., van Doorn L., Hu S., van Gerven L., de Bruijn P., Li L., Gibson A.A., Mathijssen R.H., Sparreboom A. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin. Pharmacol. Ther. 2013, 94:585-592.
117. Srinivasula S.M., Ahmad M., Fernandes-Alnemri T., Litwack G., Alnemri E.S. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl. Acad. Sci. U.S.A 1996, 93:14486-14491.
118. Suk R., Gurubhagavatula S., Park S., Zhou W., Su L., Lynch T.J., Wain J.C., Neuberg D., Liu G., Christiani D.C. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin. Cancer Res. 2005, 11:1534-1538.
119. Taipale M., Jarosz D.F., Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 2010, 11:515-528.
120. Thomas A.J., Hailey D.W., Stawicki T.M., Wu P., Coffin A.B., Rubel E.W., Raible D.W., Simon J.A., Ou H.C. Functional mechanotransduction is required for Cisplatin-induced hair cell death in the zebrafish lateral line. J. Neurosci. 2013, 33:4405-4414.
121. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10:537-549.
122. Tsuruya K., Ninomiya T., Tokumoto M., Hirakawa M., Masutani K., Taniguchi M., Fukuda K., Kanai H., Kishihara K., Hirakata H., Iida M. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int. 2003, 63:72-82.
123. Viale M., Vannozzi M.O., Pastrone I., Mariggio M.A., Zicca A., Cadoni A., Cafaggi S., Tolino G., Lunardi G., Civalleri D., Lindup W.E., Esposito M. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?. J. Pharmacol. Exp. Ther. 2000, 293:829-836.
124. Vu A.A., Nadaraja G.S., Huth M.E., Luk L., Kim J., Chai R., Ricci A.J., Cheng A.G. Integrity and regeneration of mechanotransduction machinery regulate aminoglycoside entry and sensory cell death. PLoS One 2013, 8:e54794.
125. Wang J., Ladrech S., Pujol R., Brabet P., Van De Water T.R., Puel J.L. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res. 2004, 64:9217-9224.
126. Watanabe K., Inai S., Jinnouchi K., Bada S., Hess A., Michel O., Yagi T. Nuclear-factor kappa B (NF-kappa B)-inducible nitric oxide synthase (iNOS/NOS II) pathway damages the stria vascularis in cisplatin-treated mice. Anticancer Res. 2002, 22:4081-4085.
127. Wei Q., Dong G., Yang T., Megyesi J., Price P.M., Dong Z. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am. J. Physiol. Renal Physiol. 2007, 293:F1282-F1291.
128. Wisnovsky S.P., Wilson J.J., Radford R.J., Pereira M.P., Chan M.R., Laposa R.R., Lippard S.J., Kelley S.O. Targeting mitochondrial DNA with a platinum-based anticancer agent. Chem. Biol. 2013, 20:1323-1328.
129. Xu H., Robinson G.W., Huang J., Lim J.Y., Zhang H., Bass J.K., Broniscer A., Chintagumpala M., Bartels U., Gururangan S., Hassall T., Fisher M., Cohn R., Yamashita T., Teitz T., Zuo J., Onar-Thomas A., Gajjar A., Stewart C.F., Yang J.J. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat. Genet. 2015, 47:263-266.
130. Yancey A., Harris M.S., Egbelakin A., Gilbert J., Pisoni D.B., Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr. Blood Cancer 2012, 59:144-148.
131. Yang C., Kaushal V., Shah S.V., Kaushal G.P. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 2008, 294:F777-F787.
132. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007, 334:115-124.
133. Yu F., Megyesi J., Safirstein R.L., Price P.M. Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Am. J. Physiol. Renal Physiol. 2005, 289:F514-520.
134. Zamble D.B., Jacks T., Lippard S.J. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc. Natl. Acad. Sci. U.S.A 1998, 95:6163-6168.
135. Zhang M., Liu W., Ding D., Salvi R. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience 2003, 120:191-205.
136. Zhang B., Ramesh G., Norbury C.C., Reeves W.B. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 2007, 72:37-44.
137. de Jongh F.E., van Veen R.N., Veltman S.J., de Wit R., van der Burg M.E., van den Bent M.J., Planting A.S., Graveland W.J., Stoter G., Verweij J. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer 2003, 88:1199-1206.
138. van Ruijven M.W., de Groot J.C., Hendriksen F., Smoorenburg G.F. Immunohistochemical detection of platinated DNA in the cochlea of cisplatin-treated guinea pigs. Hear Res. 2005, 203:112-121.